LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,522,628
تعداد دریافت فایل اصل مقاله7,300,869
Azizi, Marzieh, Khani, Soghra, Kamali, Mahsa, Elyasi, Forouzan. (1401). The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials. سامانه مدیریت نشریات علمی, 47(3), 173-193. doi: 10.30476/ijms.2020.87687.1817
Marzieh Azizi; Soghra Khani; Mahsa Kamali; Forouzan Elyasi. "The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials". سامانه مدیریت نشریات علمی, 47, 3, 1401, 173-193. doi: 10.30476/ijms.2020.87687.1817
Azizi, Marzieh, Khani, Soghra, Kamali, Mahsa, Elyasi, Forouzan. (1401). 'The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials', سامانه مدیریت نشریات علمی, 47(3), pp. 173-193. doi: 10.30476/ijms.2020.87687.1817
Azizi, Marzieh, Khani, Soghra, Kamali, Mahsa, Elyasi, Forouzan. The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials. سامانه مدیریت نشریات علمی, 1401; 47(3): 173-193. doi: 10.30476/ijms.2020.87687.1817

The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials

Iranian Journal of Medical Sciences
مقاله 2، دوره 47، شماره 3، مرداد 2022، صفحه 173-193    اصل مقاله (364.73 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/ijms.2020.87687.1817
نویسندگان
Marzieh Azizi1، 2؛ Soghra Khani3؛ Mahsa Kamali4؛ Forouzan Elyasi* 5
1Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran
2Department of Midwifery and Reproductive Health, School of Nursing and Midwifery, Tehran University of Medical Sciences, Tehran, Iran
3Sexual and Reproductive Health Research Center, School of Nursing and Midwifery, Mazandaran University of Medical Sciences, Sari, Iran
4Department of Medical-Surgical Nursing, Nasibeh School of Nursing and Midwifery, Mazandaran University of Medical Sciences, Sari, Iran
5Department of Psychiatry, Psychiatry and Behavioral Sciences Research Center, Sexual and Reproductive Health Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran
چکیده
Background: Hot flashes (HF) are a common symptom during the menopausal transition. It is therefore important to identify effective drugs that can alleviate HF. This study aimed to systematically review published clinical trials on the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) in the treatment of HF in healthy menopausal women.
Methods: In this systematic review, articles published during 2003-2019 in PubMed, MEDLINE, Web of Science, Scopus, Science Direct, PsycINFO, CINAHL, the Cochrane Central Register of Controlled Trials, and Google Scholar as well as Iranian databases such as SID, and Magiran were searched. The quality of the selected articles was assessed using the Jadad score calculation.
Results: Thirty-six articles on randomized controlled trials were included in this study, out of which 27 articles had acceptable, and nine had weak methodological quality. Findings on SSRIs class of drugs indicated that escitalopram, paroxetine, and fluoxetine have higher efficacy and safety in the treatment of menopausal HF than other drugs. Studies on the effectiveness of sertraline, citalopram, and fluvoxamine are limited in number or show inconsistent results. Therefore, further high-quality studies are required to confirm their effectiveness in alleviating HF. Within the SNRIs class, venlafaxine and desvenlafaxine showed significant efficacy in the treatment of menopausal HF. However, studies on the effectiveness of duloxetine are also limited, which requires further research.
Conclusion: Most studies have indicated the efficacy and safety of some antidepressants, such as SSRIs and SNRIs, in decreasing the frequency and severity of HF. These drugs are therefore recommended for the treatment of menopausal HF.
کلیدواژه‌ها
Middle age؛ Psychopharmacology؛ Efficacy
سایر فایل های مرتبط با مقاله
مراجع
  1. Freedman RR. Physiology of hot flashes. Am J Hum Biol. 2001;13:453-64. doi: 10.1002/ajhb.1077. PubMed PMID: 11400216.
  2. Defronzo Dobkin R, Menza M, Allen LA, Marin H, Bienfait KL, Tiu J, et al. Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study. Ann Clin Psychiatry. 2009;21:70-6. PubMed PMID: 19439155; PubMed Central PMCID: PMCPMC2683354.
  3. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. 2005;23:6919-30. doi: 10.1200/JCO.2005.10.081. PubMed PMID: 16192581.
  4. Archer DF, Sturdee DW, Baber R, de Villiers TJ, Pines A, Freedman RR, et al. Menopausal hot flushes and night sweats: where are we now? Climacteric. 2011;14:515-28. doi: 10.3109/13697137.2011.608596. PubMed PMID: 21848495.
  5. Carroll DG, Lisenby KM, Carter TL. Critical appraisal of paroxetine for the treatment of vasomotor symptoms. Int J Womens Health. 2015;7:615-24. doi: 10.2147/IJWH.S50804. PubMed PMID: 26124682; PubMed Central PMCID: PMCPMC4476484.
  6. Freedman RR. Menopausal hot flashes: mechanisms, endocrinology, treatment. J Steroid Biochem Mol Biol. 2014;142:115-20. doi: 10.1016/j.jsbmb.2013.08.010. PubMed PMID: 24012626; PubMed Central PMCID: PMCPMC4612529.
  7. Davis SR, Lambrinoudaki I, Lumsden M, Mishra GD, Pal L, Rees M, et al. Menopause. Nat Rev Dis Primers. 2015;1:15004. doi: 10.1038/nrdp.2015.4. PubMed PMID: 27188659.
  8. Worsley R, Bell RJ, Gartoulla P, Davis SR. Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women. Menopause. 2016;23:11-7. doi: 10.1097/GME.0000000000000495. PubMed PMID: 26240945.
  9. Islam RM, Bell RJ, Billah B, Hossain MB, Davis SR. Prevalence and severity of vasomotor symptoms and joint pain in women at midlife in Bangladesh: a population-based survey. Menopause. 2016;23:731-9. doi: 10.1097/GME.0000000000000615. PubMed PMID: 26926325.
  10. Gartoulla P, Bell RJ, Worsley R, Davis SR. Moderate-severely bothersome vasomotor symptoms are associated with lowered psychological general wellbeing in women at midlife. Maturitas. 2015;81:487-92. doi: 10.1016/j.maturitas.2015.06.004. PubMed PMID: 26115590.
  11. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21:924-32. doi: 10.1097/GME.0000000000000196. PubMed PMID: 24473530; PubMed Central PMCID: PMCPMC4574289.
  12. Carpenter JS, Guthrie KA, Larson JC, Freeman EW, Joffe H, Reed SD, et al. Effect of escitalopram on hot flash interference: a randomized, controlled trial. Fertil Steril. 2012;97:1399-404 e1. doi: 10.1016/j.fertnstert.2012.03.001. PubMed PMID: 22480818; PubMed Central PMCID: PMCPMC3367120.
  13. Anderson D, Posner N. Relationship between psychosocial factors and health behaviours for women experiencing menopause. Int J Nurs Pract. 2002;8:265-73. doi: 10.1046/j.1440-172x.2002.00376.x. PubMed PMID: 12225353.
  14. Borissova AM, Kovatcheva R, Shinkov A, Vukov M. A study of the psychological status and sexuality in middle-aged Bulgarian women: significance of the hormone replacement therapy (HRT). Maturitas. 2001;39:177-83. doi: 10.1016/s0378-5122(01)00191-8. PubMed PMID: 11514116.
  15. Schober CE, Ansani NT. Venlafaxine hydrochloride for the treatment of hot flashes. Ann Pharmacother. 2003;37:1703-7. doi: 10.1345/aph.1C483. PubMed PMID: 14565812.
  16. van Gool AR, Bannink M, Bontenbal M, Seynaeve C. Clinical experience with venlafaxine in the treatment of hot flushes in women with a history of breast cancer. Neth J Med. 2005;63:175-8. PubMed PMID: 15952486.
  17. Nagata H, Nozaki M, Nakano H. Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies. J Obstet Gynaecol Res. 2005;31:107-14. doi: 10.1111/j.1447-0756.2005.00254.x. PubMed PMID: 15771635.
  18. Shen W, Stearns V. Treatment strategies for hot flushes. Expert Opin Pharmacother. 2009;10:1133-44. doi: 10.1517/14656560902868217. PubMed PMID: 19405789.
  19. Imai A, Matsunami K, Takagi H, Ichigo S. New generation nonhormonal management for hot flashes. Gynecol Endocrinol. 2013;29:63-6. doi: 10.3109/09513590.2012.705380. PubMed PMID: 22809093.
  20. Sikon A, Thacker HL. Treatment options for menopausal hot flashes. Cleve Clin J Med. 2004;71:578-82. doi: 10.3949/ccjm.71.7.578. PubMed PMID: 15320367.
  21. Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA. 2011;305:267-74. doi: 10.1001/jama.2010.2016. PubMed PMID: 21245182; PubMed Central PMCID: PMCPMC3129746.
  22. Simon JA, Portman DJ, Kaunitz AM, Mekonnen H, Kazempour K, Bhaskar S, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013;20:1027-35. doi: 10.1097/GME.0b013e3182a66aa7. PubMed PMID: 24045678.
  23. Soares CN, Joffe H, Viguera AC, Petrillo L, Rydzewski M, Yehezkel R, et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. Am J Med. 2008;121:159-62 e1. doi: 10.1016/j.amjmed.2007.10.007. PubMed PMID: 18261506.
  24. Thurston RC. SSRIs for menopausal hot flashes: a promise yet to be delivered. Menopause. 2007;14:820-2. doi: 10.1097/gme.0b013e31812714c8. PubMed PMID: 17667151.
  25. Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause. 2006;13:568-75. doi: 10.1097/01.gme.0000196595.82452.ca. PubMed PMID: 16837878.
  26. Freeman MP, Hirschberg AM, Wang B, Petrillo LF, Connors S, Regan S, et al. Duloxetine for major depressive disorder and daytime and nighttime hot flashes associated with the menopausal transition. Maturitas. 2013;75:170-4. doi: 10.1016/j.maturitas.2013.03.007. PubMed PMID: 23602542.
  27. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol. 2009;200:172 e1-10. doi: 10.1016/j.ajog.2008.09.877. PubMed PMID: 19110224.
  28. Akhavan S, Zandvakili F, Arab M, Karimi H, Gharibi F. Comparison of the therapeutic effects of fluoxetine, citalopram, estrogen and progesterone and placebo in the treatment of hot flushes in perimenopausal women. Scientific Journal of Kurdistan University of Medical Sciences. 2011;16:31-8.
  29. Freedman RR, Kruger ML, Tancer ME. Escitalopram treatment of menopausal hot flashes. Menopause. 2011;18:893-6. doi: 10.1097/gme.0b013e31820ccae9. PubMed PMID: 21540755; PubMed Central PMCID: PMCPMC3181049.
  30. Grady D, Cohen B, Tice J, Kristof M, Olyaie A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol. 2007;109:823-30. doi: 10.1097/01.AOG.0000258278.73505.fa. PubMed PMID: 17400842.
  31. Slaton RM, Champion MN, Palmore KB. A review of paroxetine for the treatment of vasomotor symptoms. J Pharm Pract. 2015;28:266-74. doi: 10.1177/0897190014544785. PubMed PMID: 25107421.
  32. Weber L, Thacker HL. Paroxetine: a first for selective serotonin reuptake inhibitors - a new use: approved for vasomotor symptoms in postmenopausal women. Womens Health (Lond). 2014;10:147-54. doi: 10.2217/whe.14.3. PubMed PMID: 24601805.
  33. Wei D, Chen Y, Wu C, Wu Q, Yao L, Wang Q, et al. Effect and safety of paroxetine for vasomotor symptoms: systematic review and meta-analysis. BJOG. 2016;123:1735-43. doi: 10.1111/1471-0528.13951. PubMed PMID: 27062457.
  34. Riemma G, Schiattarella A, La Verde M, Zarobbi G, Garzon S, Cucinella G, et al. Efficacy of Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic Review and Meta-Analysis of Randomized Trials. Medicina (Kaunas). 2019;55. doi: 10.3390/medicina55090554. PubMed PMID: 31480427; PubMed Central PMCID: PMCPMC6780738.
  35. Johnson ED, Carroll DG. Venlafaxine and desvenlafaxine in the management of menopausal hot flashes. Pharm Pract (Granada). 2011;9:117-21. PubMed PMID: 24367464; PubMed Central PMCID: PMCPMC3870169.
  36. Sarita Khainju. The efficacy and tolerability of SNRI (Venlafaxine And Desvenlafaxine) for the treatment of vasomotor symptoms in menopausal women. IJSIT. 2016;5:283-302.
  37. Graziano M. Is Desvenlafaxine Effective for Reducing Hot Flashes In Postmenopausal Females? 2016. PCOM Physician Assistant Studies Student Scholarship. 2016:284.
  38. Handley AP, Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract. 2015;27:54-61. doi: 10.1002/2327-6924.12137. PubMed PMID: 24944075.
  39. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100. doi: 10.1371/journal.pmed.1000100. PubMed PMID: 19621070; PubMed Central PMCID: PMCPMC2707010.
  40. Halpern SH, Douglas MJ. Appendix: Jadad scale for reporting randomized controlled trials. Evidence-based Obstetric Anesthesia Oxford, UK: Blackwell Publishing Ltd. 2005:237-8. doi: 10.1002/9780470988343.app1.
  41. Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials. 2009;4:79-88. doi: 10.2174/157488709788186021. PubMed PMID: 19463104; PubMed Central PMCID: PMCPMC2694951.
  42. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. doi: 10.1016/0197-2456(95)00134-4. PubMed PMID: 8721797.
  43. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA. 2003;289:2827-34. doi: 10.1001/jama.289.21.2827. PubMed PMID: 12783913.
  44. Kerwin JP, Gordon PR, Senf JH. The variable response of women with menopausal hot flashes when treated with sertraline. Menopause. 2007;14:841-5. doi: 10.1097/GME.0b013e31802e7f22. PubMed PMID: 17413648.
  45. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005;105:161-6. doi: 10.1097/01.AOG.0000147840.06947.46. PubMed PMID: 15625158.
  46. Caan B, LaCroix AZ, Joffe H, Guthrie KA, Larson JC, Carpenter JS, et al. Effects of estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo-controlled randomized trial. Menopause. 2015;22:607-15. doi: 10.1097/GME.0000000000000364. PubMed PMID: 25405571; PubMed Central PMCID: PMCPMC4610378.
  47. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, Study I. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol. 2009;200:238 e1- e10. doi: 10.1016/j.ajog.2008.10.057. PubMed PMID: 19167693.
  48. Speroff L, Gass M, Constantine G, Olivier S, Study I. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol. 2008;111:77-87. doi: 10.1097/01.AOG.0000297371.89129.b3. PubMed PMID: 18165395.
  49. Pinkerton JV, Joffe H, Kazempour K, Mekonnen H, Bhaskar S, Lippman J. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. Menopause. 2015;22:50-8. doi: 10.1097/GME.0000000000000311. PubMed PMID: 25137243; PubMed Central PMCID: PMCPMC4274337.
  50. Simon JA, Chandler J, Gottesdiener K, Lazarus N, He W, Rosenberg E, et al. Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetine. Menopause. 2014;21:938-44. doi: 10.1097/GME.0000000000000218. PubMed PMID: 24569618.
  51. Pinkerton JV, Constantine G, Hwang E, Cheng RF, Study I. Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial. Menopause. 2013;20:28-37. doi: 10.1097/gme.0b013e31826421a8. PubMed PMID: 23010882.
  52. Pinkerton JV, Archer DF, Guico-Pabia CJ, Hwang E, Cheng RF. Maintenance of the efficacy of desvenlafaxine in menopausal vasomotor symptoms: a 1-year randomized controlled trial. Menopause. 2013;20:38-46. doi: 10.1097/GME.0b013e318274699f. PubMed PMID: 23266839.
  53. Ensrud KE, Joffe H, Guthrie KA, Larson JC, Reed SD, Newton KM, et al. Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause. 2012;19:848-55. doi: 10.1097/gme.0b013e3182476099. PubMed PMID: 22433978; PubMed Central PMCID: PMCPMC3382013.
  54. Ghomian N, Tavasoli F, Lotfalizadeh M. Comparison of fluoxetine with a placebo in treating postmenopausal hot flash. Journal of Birjand University of Medical Sciences. 2008;15:5-11. Persian
  55. Yazdizadeh V, Kazemnejad A, Modares Gilani M. The effect of fluoxetin on hot flashes in menopaused women. Daneshvar Medicine: Basic and Clinical Research Journal. 2009;16:23-8. Persian.
  56. Amin G, Mousavi Pharm A, Vosough S, Jafary Azar Z, Shariat M, Haghollahi F, et al. Therapeutic effect of combination of Nigella sativa, Melissa officinalis extract and fennel fruit with citalopram on menopausal symptoms. Tehran University Medical Journal TUMS Publications. 2018;76:417-25. Persian.
  57. Molaie M, Darvishi B, Jafari Azar Z, Shirazi M, Amin G, Afshar S. Effects of a combination of Nigella sativa and Vitex agnus-castus with citalopram on healthy menopausal women with hot flashes: results from a subpopulation analysis. Gynecol Endocrinol. 2019;35:58-61. doi: 10.1080/09513590.2018.1499086. PubMed PMID: 30129806.
  58. Rahmanian M, Mohseni A, Ghorbani R. A crossover study comparing gabapentin and fluoxetine for the treatment of vasomotor symptoms among postmenopausal women. Int J Gynaecol Obstet. 2015;131:87-90. doi: 10.1016/j.ijgo.2015.04.042. PubMed PMID: 26160608.
  59. Davari-Tanha F, Soleymani-Farsani M, Asadi M, Shariat M, Shirazi M, Hadizadeh H. Comparison of citalopram and venlafaxine’s role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. Arch Gynecol Obstet. 2016;293:1007-13. doi: 10.1007/s00404-015-3900-1. PubMed PMID: 26437957.
  60. Oktem M, Eroglu D, Karahan HB, Taskintuna N, Kuscu E, Zeyneloglu HB. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. Adv Ther. 2007;24:448-61. doi: 10.1007/BF02849914. PubMed PMID: 17565936.
  61. Kalay AE, Demir B, Haberal A, Kalay M, Kandemir O. Efficacy of citalopram on climacteric symptoms. Menopause. 2007;14:223-9. doi: 10.1097/01.gme.0000243571.55699.4a. PubMed PMID: 17224858.
  62. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, Bloigu R, Karjalainen E, Haiva-Mallinen L, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause. 2005;12:18-26. doi: 10.1097/00042192-200512010-00006. PubMed PMID: 15668596.
  63. Oishi A, Mochizuki Y, Otsu R, Inaba N. Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women. Biopsychosoc Med. 2007;1:12. doi: 10.1186/1751-0759-1-12. PubMed PMID: 17547780; PubMed Central PMCID: PMCPMC1899513.
  64. Joffe H, Soares CN, Petrillo LF, Viguera AC, Somley BL, Koch JK, et al. Treatment of depression and menopause-related symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine. J Clin Psychiatry. 2007;68:943-50. doi: 10.4088/jcp.v68n0619. PubMed PMID: 17592922.
  65. Lofty M, Abdelmoez K. Escitalopram versus black cohosh for relieving hot flashes in nondepressed menopausal women. Evidence Based Women’s Health Journal. 2016;6:101-5. doi: 10.1097/01.EBX.0000488776.94081.21.
  66. Zareen N, Khan M, Siddiqui FA, Siddiqui F. The role of paroxetine in postmenopausal hot-flashes frequency reduction. Pak J Med Dent. 2019;8:22-6.
  67. Bouchard P, Panay N, de Villiers TJ, Vincendon P, Bao W, Cheng RJ, et al. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. Climacteric. 2012;15:12-20. doi: 10.3109/13697137.2011.586445. PubMed PMID: 22066790.
  68. Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. Am Fam Physician. 2006;74:449-56. PubMed PMID: 16913164.
  69. Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002;14:175-82. doi: 10.1023/a:1021141404535. PubMed PMID: 12585567.
آمار
تعداد مشاهده مقاله: 6,298
تعداد دریافت فایل اصل مقاله: 3,545


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب